Literature DB >> 10499470

Faecal parameters in the assessment of activity in inflammatory bowel disease.

A van der Sluys Veer1, I Biemond, H W Verspaget, C B Lamers.   

Abstract

BACKGROUND: Determination of inflammatory activity is helpful when assessing the efficacy of drugs in therapeutic trials and in facilitating management of individual patients with inflammatory bowel disease (IBD). Faecal parameters have been hypothesized to be more specific than non-faecal measurements in the assessment of intestinal inflammation.
METHODS: Review of the literature on faecal measurements in IBD. RESULTS AND
CONCLUSIONS: Leakage of various proteins and leukocyte products into the intestinal lumen can be assessed and quantified in stool specimens and serve as a measurement of inflammatory activity. Several of these faecal parameters are raised in patients with IBD. There is a considerable overlap between patients with active and those with inactive disease, however, and the correlation of the faecal parameters with disease activity indices is often low. The value of alpha1-antitrypsin measurement in faeces in the assessment of intestinal inflammation has been well established. Further studies in patients with IBD are needed to determine whether other faecal parameters, such as lactoferrin, tumour necrosis factor alpha, PMN-elastase, lysozyme, leucocyte esterase, immunoglobulin A, among others, are more accurate or cost-effective than measurement of alpha1-antitrypsin in the stools of such patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499470     DOI: 10.1080/003655299750025624

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  9 in total

1.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

Review 2.  Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?

Authors:  D S Pardi; W J Sandborn
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Clinical significance of inflammatory markers.

Authors:  Bincy P Abraham; Selvi Thirumurthi
Journal:  Curr Gastroenterol Rep       Date:  2009-10

Review 4.  Neutrophils and inflammatory metabolism in antimicrobial functions of the mucosa.

Authors:  Eric L Campbell; Sean P Colgan
Journal:  J Leukoc Biol       Date:  2015-02-24       Impact factor: 4.962

Review 5.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

Review 6.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis.

Authors:  Ibrahim Masoodi; Rakesh Kochhar; Usha Dutta; Chetana Vaishnavi; K K Prasad; Kim Vaiphei; Shabnum Hussain; Kartar Singh
Journal:  Dig Dis Sci       Date:  2012-02-16       Impact factor: 3.199

Review 8.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 9.  Biomarkers in the management of ulcerative colitis: a brief review.

Authors:  Ibrahim Masoodi; Bashir M Tijjani; Hamidullah Wani; Nadeem Syed Hassan; Arshad Bashir Khan; Shabnum Hussain
Journal:  Ger Med Sci       Date:  2011-02-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.